Synthesis, characterization and pharmacological evaluation of pyrazolyl urea derivatives as potential anti-inflammatory agents

Abstract

p38α mitogen activated protein kinase (MAPK) inhibitors provide a novel approach for the treatment of inflammatory disorders. A series of fifteen pyrazolyl urea derivatives (3a—o) were synthesized and evaluated for their p38α MAPK inhibition and antioxidant potential. Compounds 3a—e, 3g and 3h showed low micromolar range potency (IC50 values ranging from 0.037 ± 1.56 to 0.069 ± 0.07 µmol/L) compared to the standard inhibitor SB 203580 (IC50 = 0.043 ± 3.62 µmol/L) when evaluated for p38α MAPK inhibition by an immunosorbent-based assay. Antioxidant activity was measured by a 2,2′-diphenyl-1-picryl hydrazyl radical (DPPH) free radical scavenging method and one of the compounds, 3c, showed better percentage antioxidant activity (75.06%) compared to butylated hydroxy anisole (71.53%) at 1 mmol/L concentration. Compounds 3a—e, 3g and 3h showed promising in vivo anti-inflammatory activity (ranging from 62.25% to 80.93%) in comparison to diclofenac sodium (81.62%). The ulcerogenic liability and lipid peroxidation activity of these compounds were observed to be less in comparison to diclofenac sodium. These compounds also potently inhibited the lipopolysaccharide (LPS)-induced TNF-α release in mice (ID50 of 3a—c = 19.98, 11.32 and 9.67 mg/kg, respectively). Among the screened compounds, derivative 3c was found to be the most potent and its binding mode within the p38α MAPK is also reported.

Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome

“…The inflammatory cytokine IL-1 β is produced in very low amounts under normal circumstances. However, in terms of tissue damage, environmental stress, infection or chronic inflammation, the production of IL-1 β is highly increased43., 44.. The production and secretion of IL-1 β is regulated by diverse inflammasomes, including NLRP3, NLRC4, and AIM2 inflammasomes.…”

GPRC5B protects osteoarthritis by regulation of autophagy signaling

“…Osteoarthritis is a common disease that lacks an effective strategy to treat the underlying pathophysiology. Celecoxib, a current popular OA treatment, is used to relieve pain and inflammation but does not delay cartilage degeneration 27 , 28 , 29 . Other commonly used treatments such as glucosamine, chondroitin sulfate, and hyaluronic acid, are controversial in their ability to alleviate symptoms in OA patients 30 , 31 .…”

Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years

“…Pyrazole is a π -excess aromatic heterocycle, which has been recognized as a pharmacologically important active scaffold for organic synthesis, especially for new COX-2 inhibitor development. Clinical agents containing pyrazole fragments are celecoxib, antipyrine, aminopyrine, and metamizole 21 . During the past ten years, a number of pyrazole derivatives were reported and screened for their COX-2 inhibition and anti-inflammatory activity ( Fig.…”